Administration of the CD122 (IL-2Rβ) IL2 pathway agonist bempegaldesleukin (known as NKTR-214), together with anti-PD-1, to B2M-knockout mice, markedly suppressed tumor growth and significantly increased mouse survival [47]. This evidence concerns the gene B2M and neoplasm.